Evidence map›Paper›PMID 36395510›Full record

ArticleBiomedical materials (Bristol, England)2022

3D bioprinting optimization of human mesenchymal stromal cell laden gelatin-alginate-collagen bioink.

Stephen W Sawyer, Kazuyo Takeda, Alaadin Alayoubi, Eman Mirdamadi, Ahmed Zidan, Steven R Bauer, Heba Degheidy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical materials (Bristol, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. [Cell therapy and wound repair].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2024
    Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Stephen W SawyerCenter for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration, Silver Spring, MD, United States of America.ORCID 0000-0002-4453-0957
Kazuyo TakedaCenter for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration, Silver Spring, MD, United States of America.
Alaadin AlayoubiCenter for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD, United States of America.
Eman MirdamadiDepartment of Bioengineering, University of Maryland, College Park, MD, United States of America.
Ahmed ZidanCenter for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD, United States of America.
Steven R BauerCenter for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration, Silver Spring, MD, United States of America.
Heba DegheidyCenter for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration, Silver Spring, MD, United States of America.

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

3D bioprinting technology has gained increased attention in the regenerative medicine and tissue engineering communities over the past decade with their attempts to create functional living tissues and organs

Indexed as

GelatinMesenchymal Stem CellsAlginatesCollagenHumansReproducibility of ResultsAlginatesCollagenGelatin3D printingbioinkbioprintingcellular encapsulationgelatin-alginate-collagenhuman mesenchymal stromal cellsMSCs

Identifiers

PMID36395510
PMCPMC12993833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.